目的 总结儿童重症监护室患儿进行血浆置换治疗（therapeutic plasma exchange，TPE）的适应证和并发症。 方法 回顾性分析2015年3月至2021年3月在湖南省儿童医院重症医学科行TPE患儿的病历资料，分析TPE适应证和并发症，并与美国血液分离学会（American Society for Apheresis，ASFA）适应证类别比较。 结果 196例患儿共进行了405次TPE，76例（38.8%）患儿联合了连续性肾脏替代治疗，147例（75.0%）患儿存活，其中神经疾病存活率最高（27/29，93%）。TPE适应证前3位分别是血液病（61/196，31.1%）、脓毒血症合并多器官功能障碍综合征（41/196，20.9%）、肝病（36/196，18.4%）。血液病患儿接受TPE总次数最多，为129次。研究对象适应证占比最高为ASFA Ⅲ类（150/196，76.5%），其次为ASFA Ⅰ类（22/196，11.2%），ASFA Ⅱ类（14/196，7.1%），不便分类（10/196，5.1%），无ASFA Ⅳ类。TPE并发症发生率为12.3%（50/405），以管路凝血（4.2%，17/405）和低血压（3.7%，15/405）为常见，无严重不良反应。 结论 TPE在经验丰富的儿童重症监护室可以安全地用于有适应证的儿童危重症患者救治。
Abstract
Objective To study the indication for therapeutic plasma exchange (TPE) and related complications in children admitted to the pediatric intensive care unit. Methods A retrospective analysis was performed on the medical records of the children who received TPE in the Pediatric Intensive Care Unit, Hunan Children's Hospital, from March 2015 to March 2021. The indication for TPE and related complications were analyzed and compared with the American Society for Apheresis (ASFA) indication categories. Results A total of 405 TPE treatment sessions were performed for 196 children, among whom 76 children (38.8%) also received continuous renal replacement therapy and 147 children (75.0%) survived. The children with neurological diseases had the highest survival rate of 93.1% (27/29). The top three indications for TPE were hematologic diseases (61/196, 31.1%), sepsis with multiple organ dysfunction (41/196, 20.9%), and liver diseases (36/196, 18.4%). The children with hematologic diseases received the highest number of 129 TPE treatment sessions. The subjects with ASFA category Ⅲ indications accounted for the highest proportion of 76.5% (150/196), followed by those with ASFA category Ⅰ indications (11.2%, 22/196), ASFA category Ⅱ indications (7.1%, 14/196), and unknown category (5.1%, 10/196), and no ASFA category Ⅳ indications were observed. The incidence rate of TPE complications was 12.3% (50/405), and the most common complications were pipeline coagulation (4.2%, 17/405) and hypotension (3.7%, 15/405). No serious adverse events were observed. Conclusions TPE can be safely used for the treatment of critically ill children with indications in an experienced pediatric intensive care unit.
关键词
血浆置换 /
适应证 /
并发症 /
儿童
Key words
Therapeutic plasma exchange /
Indication /
Complication /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: review of current indications[J]. Transfus Apher Sci, 2019, 58(3): 247-253. PMID: 31023623. DOI: 10.1016/j.transci.2019.04.007.
2 Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue[J]. J Clin Apher, 2019, 34(3): 171-354. PMID: 31180581. DOI: 10.1002/jca.21705.
3 Duyu M, Turkozkan C. Therapeutic plasma exchange in the pediatric intensive care unit: a single-center 5-year experience[J]. Transfus Apher Sci, 2020, 59(5): 102959. PMID: 33011077. DOI: 10.1016/j.transci.2020.102959.
4 Alhasan KA. Therapeutic plasma exchange for children with kidney disorders: definitions, prescription, indications, and complications[J]. Saudi J Kidney Dis Transpl, 2019, 30(2): 291-298. PMID: 31031364. DOI: 10.4103/1319-2442.256835.
5 Weiss PF, Klink AJ, Friedman DF, et al. Pediatric therapeutic plasma exchange indications and patterns of use in US children's hospitals[J]. J Clin Apher, 2012, 27(6): 287-294. PMID: 22811262. DOI: 10.1002/jca.21242.
6 Paglialonga F, Schmitt CP, Shroff R, et al. Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units[J]. Pediatr Nephrol, 2015, 30(1): 103-111. PMID: 25135618. DOI: 10.1007/s00467-014-2907-3.
7 S?k G, Demirbuga A, Annayev A, et al. Therapeutic plasma exchange in pediatric intensive care: indications, results and complications[J]. Ther Apher Dial, 2020, 24(2): 221-229. PMID: 31922326. DOI: 10.1111/1744-9987.13474.
8 Huang P, Huang C, Xu H, et al. Early use of blood purification in severe Epstein-Barr virus-associated hemophagocytic syndrome[J]. Pediatrics, 2020, 145(6): e20193197. PMID: 32430444. DOI: 10.1542/peds.2019-3197.
9 Bustos BR, Hickmann OL, Cruces RP, et al. Therapeutic plasma exchange in critically ill children: experience of the pediatric intensive care unit of two centers in Chile[J]. Transfus Apher Sci, 2021, 60(5): 103181. PMID: 34238709. DOI: 10.1016/j.transci.2021.103181.
10 Cortina G, McRae R, Chiletti R, et al. Therapeutic plasma exchange in critically ill children requiring intensive care[J]. Pediatr Crit Care Med, 2018, 19(2): e97-e104. PMID: 29401139. DOI: 10.1097/PCC.0000000000001400.
11 Keith PD, Wells AH, Hodges J, et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience[J]. Crit Care, 2020, 24(1): 518. PMID: 32831133. PMCID: PMC7443810. DOI: 10.1186/s13054-020-03241-6.
12 Kawai Y, Cornell TT, Cooley EG, et al. Therapeutic plasma exchange may improve hemodynamics and organ failure among children with sepsis-induced multiple organ dysfunction syndrome receiving extracorporeal life support[J]. Pediatr Crit Care Med, 2015, 16(4): 366-374. PMID: 25599148. PMCID: PMC4424057. DOI: 10.1097/PCC.0000000000000351.
13 Long EJ, Taylor A, Delzoppo C, et al. A randomised controlled trial of plasma filtration in severe paediatric sepsis[J]. Crit Care Resusc, 2013, 15(3): 198-204. PMID: 23944206.
14 李娟珍, 王莹. PICU中儿童脓毒症临床特点和预后相关因素分析[J]. 临床儿科杂志, 2017, 35(10): 762-768. DOI: 10.3969/j.issn.1000-3606.2017.10.012.
15 Roth K, Strickland J, Copple BL. Regulation of macrophage activation in the liver after acute injury: role of the fibrinolytic system[J]. World J Gastroenterol, 2020, 26(16): 1879-1887. PMID: 32390699. PMCID: PMC7201151. DOI: 10.3748/wjg.v26.i16.1879.
16 Wree A, Holtmann TM, Inzaugarat ME, et al. Novel drivers of the inflammatory response in liver injury and fibrosis[J]. Semin Liver Dis, 2019, 39(3): 275-282. PMID: 31100758. DOI: 10.1055/s-0039-1685515.
17 Chris-Olaiya A, Kapoor A, Ricci KS, et al. Therapeutic plasma exchange in liver failure[J]. World J Hepatol, 2021, 13(8): 904-915. PMID: 34552697. PMCID: PMC8422921. DOI: 10.4254/wjh.v13.i8.904.
18 贺杰, 张新萍, 周雄, 等. 双重血浆分子吸附系统在儿童急性肝衰竭中的应用[J]. 中国当代儿科杂志, 2021, 23(2): 180-185. PMID: 33627215. PMCID: PMC7921536. DOI: 10.7499/j.issn.1008-8830.2010145.
19 Kathemann S, Bechmann LP, Sowa JP, et al. Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center[J]. Ann Hepatol, 2015, 14(5): 722-728. PMID: 26256901.
20 Agarwal S, Keller JR, Nunneley CE, et al. Therapeutic plasma exchange use in pediatric neurologic disorders at a tertiary care center: a 10-year review[J]. J Child Neurol, 2018, 33(2): 140-145. PMID: 29334853. DOI: 10.1177/0883073817749368.
21 Mohy-Eldeen ZM, Ahmad AR, Mahran HH, et al. Comparative study of various therapeutic modalities for Guillain Barré syndrome in Assiut University Children Hospital[J]. Turk J Pediatr, 2020, 62(6): 962-969. PMID: 33372434. DOI: 10.24953/turkjped.2020.06.007.
22 Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey[J]. J Neurol, 2020, 267(12): 3565-3577. PMID: 32623595. PMCID: PMC7954658. DOI: 10.1007/s00415-020-10026-y.
23 Gelincik A, Cavkaytar O, Kuyucu S. An update on the management of severe cutaneous drug hypersensitivity reactions[J]. Curr Pharm Des, 2019, 25(36): 3881-3901. PMID: 31692425. DOI: 10.2174/1381612825666191106115556.
24 万柳. 血浆置换联合连续性血液净化治疗儿童急性肝衰竭疗效分析[D]. 衡阳: 南华大学, 2017.
25 张义刚, 肖政辉. 血浆置换联合连续性血液净化治疗儿童噬血细胞综合征的疗效分析[J]. 实用休克杂志(中英文), 2018, 2(4): 224-229.
26 Lu J, Zhang L, Xia C, et al. Complications of therapeutic plasma exchange: a retrospective study of 1201 procedures in 435 children[J]. Medicine (Baltimore), 2019, 98(50): e18308. PMID: 31852113. PMCID: PMC6922502. DOI: 10.1097/MD.0000000000018308.
基金
湖南省急危重症急救能力提升与突发公共卫生应急救治关键技术协同创新工程（2020SK1014-3）。
PDF(524 KB)
